- Home
- PSTL vs AVIR Comparison
PSTL vs AVIR Comparison
Compare PSTL & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTL
- AVIR
- Stock Information
- Founded
- PSTL 2018
- AVIR 2012
- Country
- PSTL United States
- AVIR United States
- Employees
- PSTL N/A
- AVIR N/A
- Industry
- PSTL Real Estate Investment Trusts
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- PSTL Real Estate
- AVIR Health Care
- Exchange
- PSTL Nasdaq
- AVIR Nasdaq
- Market Cap
- PSTL 320.0M
- AVIR 290.4M
- IPO Year
- PSTL 2019
- AVIR 2020
- Fundamental
- Price
- PSTL $14.33
- AVIR $3.46
- Analyst Decision
- PSTL Buy
- AVIR Hold
- Analyst Count
- PSTL 2
- AVIR 1
- Target Price
- PSTL $15.75
- AVIR $6.88
- AVG Volume (30 Days)
- PSTL 79.3K
- AVIR 251.7K
- Earning Date
- PSTL 10-28-2024
- AVIR 11-06-2024
- Dividend Yield
- PSTL 6.67%
- AVIR N/A
- EPS Growth
- PSTL N/A
- AVIR N/A
- EPS
- PSTL 0.09
- AVIR N/A
- Revenue
- PSTL $68,445,000.00
- AVIR N/A
- Revenue This Year
- PSTL N/A
- AVIR N/A
- Revenue Next Year
- PSTL $12.21
- AVIR N/A
- P/E Ratio
- PSTL $165.15
- AVIR N/A
- Revenue Growth
- PSTL 15.46
- AVIR N/A
- 52 Week Low
- PSTL $12.98
- AVIR $2.77
- 52 Week High
- PSTL $15.15
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- PSTL 41.96
- AVIR 40.35
- Support Level
- PSTL $14.50
- AVIR $3.30
- Resistance Level
- PSTL $14.68
- AVIR $3.41
- Average True Range (ATR)
- PSTL 0.19
- AVIR 0.15
- MACD
- PSTL -0.05
- AVIR -0.03
- Stochastic Oscillator
- PSTL 8.82
- AVIR 11.18
About PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).